BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33989088)

  • 1. Costs of minor bleeds in atrial fibrillation patients using a non-vitamin K antagonist oral anticoagulant.
    Mitrovic D; Plomp M; Folkeringa R; Veeger N; Feenstra T; van Roon E
    Curr Med Res Opin; 2021 Sep; 37(9):1461-1466. PubMed ID: 33989088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minor bleeding in patients with atrial fibrillation using a non-vitamin-K antagonist oral anticoagulant.
    Mitrovic D; Folkeringa R; Veeger N; van Roon E
    Curr Med Res Opin; 2020 Oct; 36(10):1571-1576. PubMed ID: 32573287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of minor bleeds on confidence in anticoagulation therapy, adherence to treatment and quality of life in patients using a non-vitamin K antagonist oral anticoagulant for atrial fibrillation.
    Mitrovic D; Veeger N; van Roon E
    Curr Med Res Opin; 2022 Sep; 38(9):1485-1488. PubMed ID: 35656940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy.
    Metzgier-Gumiela A; Skonieczny G; Konieczyńska M; Desteghe L; Heidbuchel H; Undas A
    Int J Clin Pract; 2020 Jun; 74(6):e13483. PubMed ID: 32003070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
    Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
    Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.
    Wang CL; Wu VC; Chang KH; Tu HT; Kuo CF; Huang YT; Chu PH; Kuo CC; Chang SH
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):147-154. PubMed ID: 31384926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study.
    Forslund T; Wettermark B; Andersen M; Hjemdahl P
    Europace; 2018 Mar; 20(3):420-428. PubMed ID: 28177459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
    Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
    JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
    Bouillon K; Bertrand M; Maura G; Blotière PO; Ricordeau P; Zureik M
    Lancet Haematol; 2015 Apr; 2(4):e150-9. PubMed ID: 26687957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
    Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.